Similar articles

• Choosing treatment for a PFO-related neurologic event.

  Romanic BM, Wolfe W. Romanic BM, et al. JAAPA. 2000 Mar;13(3):89-90, 93. JAAPA. 2000. PMID: 11503406 No abstract available.
• [Reasons for underuse of oral anticoagulation in atrial fibrillation-associated stroke: prospective study of German stroke patients].

  Reicke B, Masuhr F, Weih M. Reicke B, et al. Fortschr Neurol Psychiatr. 2008 Jul;76(7):391-5. doi: 10.1055/s-2008-1038216. Fortschr Neurol Psychiatr. 2008. PMID: 18604772 German.
• Patent foramen ovale and the risk of cryptogenic stroke.

  Schrale RG, Mitchell AR, Ormerod OJ. Schrale RG, et al. J Am Coll Cardiol. 2006 Nov 7;48(9):1913-4; author reply 1914. doi: 10.1016/j.jacc.2006.08.003. Epub 2006 Oct 17. J Am Coll Cardiol. 2006. PMID: 17084271 No abstract available.
• Percutaneous devices for stroke prevention.

  Bayard YL, Ostermayer SH, Hein R, Skowasch M, Büscheck F, Baranowski A, Heinisch C, Sievert H. Bayard YL, et al. Cardiovasc Revasc Med. 2007 Jul-Sep;8(3):216-25. doi: 10.1016/j.carrev.2007.01.005. Cardiovasc Revasc Med. 2007. PMID: 17765654 Review.
• Anticoagulation: stroke prevention in patients with atrial fibrillation.

  Waldo AL. Waldo AL. Med Clin North Am. 2008 Jan;92(1):143-59, xi. doi: 10.1016/j.mcna.2007.08.007. Med Clin North Am. 2008. PMID: 18061002 Review.